Recombumin® Alpha - rAlbumin Human
Derived from our proprietary S. cerevisiae yeast expression technology Recombumin Alpha USP-NF* has been developed to deliver quality and unprecedented performance benefits in our customers' applications including drug and vaccine manufacture, device coating, IVF media, specialized cell culture and cell therapy applications. Benefits: Animal-free Secure supply in large volume quantities cGMP for regulatory-compliance…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Derived from our proprietary S. cerevisiae yeast expression technology Recombumin Alpha USP-NF* has been developed to deliver quality and unprecedented performance benefits in our customers' applications including drug and vaccine manufacture, device coating, IVF media, specialized cell culture and cell therapy applications.
Benefits:
- Animal-free
- Secure supply in large volume quantities
- cGMP for regulatory-compliance and consistency
- Exceptional purity profile
- Consistent quality for reduced lot testing or vendor auditing
- Convenient liquid format
Applications:
- Drug manufacturing
- Half-life extension of peptides
- Drug targeting and delivery
- Albumin micro- and nanoparticle-based drugs. - Medical devices
- Coating
- IVF and advanced cell therapy media ingredient. - Cell culture
- Stem and therapeutic cell culture
- Industrial mammalian cell culture
Improved Stabilization and Reduction of Particulate Formation in Protein Drug Formulations Using Recombinant Human Albumin (rAlbumin Human USP-NF)
This poster demonstrates that a recombinant HSA (rAlbumin) derived from yeast is a safe excipient candidate with a well-documented stabilizing effect including aggregation prevention in liquid and lyophilized protein formulations and also prevention of drug depletion and degradation caused by surface adsorption/effects.
